“Influence of Baseline Demographics Disease Characteristics on Efficacy of an Oral Selective TYK2 Inhibitor, BMS-986165, in Patients With Moderate to Severe Plaque Psoriasis: Phase 2, Randomized, Placebo-Controlled Trial”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S14. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/741.